Science Corporation implants its vision-restoring chip in its first Stargardt disease patient
- ID
- 35067
- Status
- summarized
- Published
- 14 Oct 2026, 7:13 AM
- Fetched
- 14 Oct 2026, 2:33 PM
- Provider
- TechCrunch
- Category
- technology
- Original URL
- https://techcrunch.com/2026/10/13/science-corporation-implants-its-vision-restoring-chip-in-its-first-stargardt-disease-patient/
- Source URL
- https://techcrunch.com/feed/
Summary
- Score
- 2.5
- Created
- 14 Oct 2026, 2:33 PM
- Tags
- Audience
- developersai_ml_learners
What happened
Science Corporation CEO Max Hodak announced at TechCrunch Disrupt that the company has implanted its PRIMA vision-restoring chip into its first Stargardt disease patient. PRIMA is already commercially available in Europe for patients who lost sight to geographic atrophy, an advanced form of age-related macular degeneration, and Science Corporation is now testing whether the same device approach works for Stargardt disease, an inherited condition affecting roughly 150,000 people worldwide that destroys the outer retina while potentially sparing the inner retina. Hodak framed retinal prostheses, cochlear implants, and motor prostheses as all being forms of brain-computer interface rather than computer-control devices.
Why it matters
This is a medical-device milestone, not something most builders can act on this week — no pricing, no developer API, no availability outside the existing European geographic-atrophy indication, and no Malaysia or Southeast Asia detail in the text. The one transferable idea worth noting is Hodak's framing that the retina is part of the central nervous system, so BCI work is broader than cursor control; that is a positioning argument from a company founder on stage, not a measured result, and the excerpt gives no efficacy data, patient outcomes, or trial timeline.
Discussion angle
Hodak's claim that retinal and cochlear implants are 'all different types of BCI' is a definitional move that widens the BCI category well beyond neurotech-for-computing — does redefining the term help or blur how we evaluate claims about brain interfaces?